Introduction to the application of QbD principles for the development of monoclonal antibodies

详细信息    查看全文

• 作者：Christof Finkler^a ; ^{christof.finkler@roche.com" class="auth_mail" title="E-mail the corresponding author} ; Lynne Krummen^b
• 关键词：Quality by Design
• 刊名：Biologicals
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：44
• 期：5
• 页码：282-290
• 全文大小：1876 K

文摘

Quality by Design (QbD) is a global regulatory initiative with the goal of enhancing pharmaceutical development through the proactive design of pharmaceutical manufacturing process and controls to consistently deliver the intended performance of the product. The principles of pharmaceutical development relevant to QbD are described in the ICH guidance documents (ICHQ8-11). An integrated set of risk assessments and their related elements developed at Roche/Genentech were designed to provide an overview of product and process knowledge for the production of a recombinant monoclonal antibody.

This chapter introduces a publication series on the application of Quality by Design for biopharmaceuticals, with a focus on the development of recombinant monoclonal antibodies. The development of and overview on the QbD concept applied by Roche and Genentech is described and essential QbD elements are presented.